These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
19 related articles for article (PubMed ID: 15851780)
1. Re: Berenson J, Hirschberg R. Safety and convenience of a 15-minute infusion of zoledronic acid. Diel IJ; Bergner R Oncologist; 2005 Jan; 10(1):82-3; author reply 84-7. PubMed ID: 15632256 [No Abstract] [Full Text] [Related]
2. Symptomatic hypocalcemia following intravenous administration of zoledronic acid in a breast cancer patient. Mishra A J Postgrad Med; 2008; 54(3):237. PubMed ID: 18626181 [No Abstract] [Full Text] [Related]
4. Long interval zoledronic acid use in bone metastases. Das M Lancet Oncol; 2017 Feb; 18(2):e72. PubMed ID: 28089632 [No Abstract] [Full Text] [Related]
5. Regarding "recommendations for zoledronic acid treatment of patients with bone metastases". Parles K Oncologist; 2005 May; 10(5):304-5. PubMed ID: 15851780 [No Abstract] [Full Text] [Related]
6. Recommendations for zoledronic acid treatment of patients with bone metastases. Berenson JR Oncologist; 2005 Jan; 10(1):52-62. PubMed ID: 15632252 [TBL] [Abstract][Full Text] [Related]
7. Denosumab and bone metastases. No better than a bisphosphonate. Prescrire Int; 2012 Sep; 21(130):204-6. PubMed ID: 23016249 [TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer. Doggrell SA Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials. Gordon DH Clin Breast Cancer; 2005 Jun; 6(2):125-31. PubMed ID: 16001990 [TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates and metastatic breast carcinoma. Lipton A Cancer; 2003 Feb; 97(3 Suppl):848-53. PubMed ID: 12548585 [TBL] [Abstract][Full Text] [Related]